US2018221301A1PendingUtilityA1

Transdermal systems containing multilayer adhesive matrices to modify drug delivery

Assignee: MYLAN TECH INCPriority: Mar 9, 2004Filed: Apr 4, 2018Published: Aug 9, 2018
Est. expiryMar 9, 2024(expired)· nominal 20-yr term from priority
A61P 5/34A61P 5/24A61P 5/30A61K 9/7053A61K 31/567A61M 37/00A61F 2013/00646A61K 9/7061A61F 13/00A61F 2013/00655A61F 2013/0071A61K 9/7092Y10T156/10A61F 2013/00906A61K 31/565A61K 9/0014
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The first polymeric adhesive matrix can release the drug more quickly or more slowly than the second polymeric adhesive matrix. Through the selection of the two matrices, the delivery profile of the drug through the skin can be selectively modified and controlled.

Claims

exact text as granted — not AI-modified
1 - 47 . (canceled) 
     
     
         48 . A transdermal drug-containing dosage unit comprising:
 a. a backing layer substantially impervious to the drug to be delivered transdermally;   b. a polymeric adhesive system comprising:
 i. a drug consisting of estradiol in an amount from 1.25% to about 4.0% w/w, 
 ii. an acrylic adhesive, 
 iii. a silicon adhesive, 
 iv. povidone, and 
 v. a solvent, wherein the polymeric adhesive system has a thickness of at least about 100 gsm; and 
   c. a release liner in contact with the polymeric adhesive system.   
     
     
         49 . The transdermal drug-containing dosage unit of  claim 48 , wherein the estradiol is estradiol hemihydrate. 
     
     
         50 . The transdermal drug-containing dosage unit of  claim 48 , wherein the polymeric adhesive system has a thickness of about 125 gsm. 
     
     
         51 . The transdermal drug-containing dosage unit of  claim 48 , wherein the polymeric adhesive system has a thickness of about 150 gsm. 
     
     
         52 . The transdermal drug-containing dosage unit of  claim 48 , wherein a thickness of the backing layer and a thickness of the polymeric adhesive system can be modified to change a drug delivery rate of the drug-containing dosage unit. 
     
     
         53 . A transdermal drug-containing dosage unit comprising:
 a. a backing layer substantially impervious to the drug to be delivered transdermally;   b. a polymeric adhesive system comprising:
 i. a drug consisting of estradiol in an amount from about 0.1% to about 4.0% w/w, 
 ii. an acrylic adhesive, 
 iii. a silicon adhesive, 
 iv. povidone, and 
 v. a solvent, wherein the polymeric adhesive system has a thickness of between about 5 and 150 gsm; and 
   c. a release liner in contact with the polymeric adhesive system.

Join the waitlist — get patent alerts

Track US2018221301A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.